Case report: Clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus

Journal of Medical Virology

Volumn 81, Issue 6, 2009, Pages 979-982

  Endo, Tomoyuki ^a   Fujimoto, Katsuya ^a   Nishio, Mitsufumi ^a   Yamamoto, Satoshi ^a   Obara, Masato ^a   Sato, Norihiro ^b   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antiretroviral therapy; HCV clearance; HIV; Protease inhibitors

Indexed keywords

ATAZANAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE; RITONAVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CHRONIC ACTIVE HEPATITIS; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MIXED INFECTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; THERAPY EFFECT; BLOOD; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; YOUNG ADULT;

EID: 66449101561     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21489     Document Type: Article

References (20)

1. Becker S. 2004. Liver toxicity in epidemiological cohorts. Clin Infect Dis 38:S49-S55. (Pubitemid 38328165)
2. Cooper CL, Cameron DW. 2002. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 35:873-879.
3. De Rosa FG, Audagnotto S, Bargiacchi O, Garazzino S, Aguilar Marucco D, Veronese L, Canta F, Bonora S, Sinicco A, Di Perri G. 2006. Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient. J Infect 53:e215-e218. (Pubitemid 44524707)
4. Falconer K, Gonzalez VD, Reichard O, Sandberg JK, Alaeus A. 2008. Spontaneous HCV clearance in HCV/HIV-1 coinfection associated with normalized CD4 counts, low level of chronic immune activation and high level of T cell function. J Clin Virol 41:160-163.
5. Fialaire P, Payan C, Vitour D, Chennebault JM, Loison J, Pichard E, Lunel F. 1999. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 180:574-575. (Pubitemid 30256353)
6. Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. 2008. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: A meta-analysis. J Antimicrob Chemother 61:1191-1200.
7. Herrero Martinez E. 2001. Hepatitis B and hepatitis C co-infection in patients with HIV. Rev Med Virol 11:253-270. (Pubitemid 32737648)
8. Kapadia SB, Chisari FV. 2005. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 102:2561-2566. (Pubitemid 40279416)
9. Koziel MJ, Peters MG. 2007. Viral hepatitis in HIV infection. N Engl J Med 356:1445-1454. (Pubitemid 46556329)
10. Leu GZ, Lin TY, Hsu JT. 2004. Anti-HCV activities of selective polyunsaturated fatty acids. Biochem Biophys Res Commun 318:275-280. (Pubitemid 38526276)
11. Liu-Young G, Kozal MJ. 2008. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 22:449-457.
12. Matsiota-Bernard P, Vrioni G, Onody C, Bernard L, de Truchis P, Peronne C. 2001. Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. Int J Antimicrob Agents 17:155-157. (Pubitemid 32101571)
13. Mohsen AH, Easterbrook P, Taylor CB, Norris S. 2002. Hepatitis C and HIV-1 coinfection. Gut 51:601-608.
14. Neau D, Trimoulet P, Winnock M, Le Bail B, Schvoerer E, Legrand E, Ragnaud JM, Dupon M, Fleury H, Lafon ME. 2001. Impact of protease inhibitors on intrahepatic hepatitis C virus viral load. AIDS 15:1736-1738. (Pubitemid 32918132)
15. Ragni MV, Bontempo FA. 1999. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 180:2027-2029.
16. Torti C, Barnes E, Quiros-Roldan E, Puoti M, Carosi G, Klenerman P. 2004. Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection. Antivir Ther 9:139-142. (Pubitemid 38313957)
17. Trimoulet P, Neau D, Le Bail B, Rullier A, Winnock M, Galperine T, Legrand E, Schvoerer E, Dupon M, Ragnaud JM, Bioulac-Sage P, Chene G, Fleury H, Lafon ME. 2002. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol 67:143-151. (Pubitemid 34493428)
18. Weissbrich B, Langmann P, Schubert J, Jassoy C, Klinker H. 2003. Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups. Eur J Med Res 8:495-498.
19. Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Fukuda Y. 2000. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: Influence of antiretroviral therapy. Blood 96:4293-4299.
20. Zeitoun JD, Mallet V, Chaix ML, Viard JP, Blanche S, Pol S. 2007. Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy. J Clin Virol 40:71-73. (Pubitemid 47307432)